Drug Profile
Research programme: anti-CD44v6 peptides - amcure
Alternative Names: AM-001 - amcureLatest Information Update: 24 Oct 2023
Price :
$50
*
At a glance
- Originator amcure
- Class Antineoplastics; Peptides
- Mechanism of Action CD44 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pancreatic cancer; Solid tumours
Most Recent Events
- 24 Oct 2023 Discontinued - Preclinical for Pancreatic cancer (Late-stage disease, Metastatic disease) in Germany (Parenteral)
- 24 Oct 2023 Discontinued - Preclinical for Solid tumors (Late-stage disease, Metastatic disease) in Germany (Parenteral)
- 28 Jun 2018 No recent reports of development identified for preclinical development in Pancreatic-cancer(Late-stage disease, Metastatic disease) in Germany (Parenteral)